The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B

• Main Authors: Shi-Long Jiang (Author), Zhi-Bin Wang (Author), Tao Zhu (Author), Ting Jiang (Author), Jiang-Feng Fei (Author), Chong Liu (Author), Chao Luo (Author), Yan Cheng (Author), Zhao-Qian Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but the frequent emergence of drug resistance remains a challenge. An understanding of the mechanisms underlying vemurafenib resistance may generate novel therapeutic strategies for patients with melanoma....